LPCN — Lipocine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1535955 ·
Last close
$2.12
Market Cap
$17.48M
52W High
$2.67
52W Low
$1.94
ADV30
47,323
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 119,397 | — | -3,849,464 | -3,671,894 | 25,358,166 | 5,015,608 | 2,527,843 |
| Dec 2025 | 1,145,390 | — | -2,515,801 | -2,370,084 | 17,005,612 | 5,205,842 | 2,528,196 |
| Sep 2025 | 114,574 | — | -3,361,040 | -3,186,832 | 16,073,167 | 3,901,040 | 1,931,119 |
| Jun 2025 | 622,849 | -1,513,920 | -2,404,353 | -2,205,716 | 18,577,193 | 6,043,980 | 1,448,773 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,760,721
Investing CF
$5,891,085
Financing CF
$2,869,552
CapEx
$-10,019
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.79
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-209,396,367
Inventory
—
Receivables
$1,159,579
ST Investments
$9,724,545
EBIT TTM
$-10,371,378
Pretax Income TTM
$-9,627,305
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,002,210
EBITDA
$-12,070,633
Free Cash Flow
$-5,964,590
Enterprise Value
$-7,251,254
Total Cash
$24,729,072
Total Debt
$0
Shares Out
8,244,253
Trailing EPS
$-1.96
Book Value
$3.05
ROE
-54.4%
ROA
-33.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,976,677 | -10,371,379 | -9,627,505 | 17,005,612 | 2,528,196 | — | -9,760,721 |
| Dec 2024 | 11,198,144 | -1,155,035 | 8,352 | 22,510,501 | 1,512,936 | — | -1,221,233 |
| Dec 2023 | -2,850,818 | -17,930,957 | -16,352,082 | 23,001,072 | 2,631,629 | — | -11,865,991 |
| Dec 2022 | 500,000 | -12,119,375 | -10,758,636 | 37,542,922 | 1,907,982 | — | -11,968,819 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics, Inc. | $17.74M | $0.04 | — |
| HOWL | Werewolf Therapeutics, Inc. | $17.15M | $0.35 | — |
| NXTC | NextCure, Inc. | $16.87M | $4.14 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $16.79M | $0.47 | — |
| DARE | Dare Bioscience, Inc. | $18.27M | $1.22 | — |
News headlines (Yahoo Finance, 1h cache)
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
2026-06-04 12:00 · Yahoo
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
2026-05-19 12:00 · Yahoo
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
2026-05-18 12:00 · Yahoo
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
2026-05-07 20:05 · Yahoo
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 19:15 · Yahoo
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
2026-05-06 13:30 · Yahoo
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
2026-04-02 12:00 · Yahoo
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
2026-03-10 12:00 · Yahoo
Lipocine: Q4 Earnings Snapshot
2026-03-10 10:25 · Yahoo
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
2026-02-27 12:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.